Kemin Industries announced April 16 that it has signed an exclusive agreement with Pacific GeneTech (PGT), a biologics company that develops and commercializes next-generation vaccines for areas of high unmet or underserved needs in food safety and animal health, to license PGT's salmonella vaccine for poultry.
PGT's salmonella vaccine addresses multiple serovars of salmonella, Kemin said, noting that PGT developed the vaccine with its proprietary Aegis platform, which is applicable to multiple pathogens, including bacteria, parasites and viruses.
Both the platform and salmonella vaccine were originally developed by the University of Arkansas's Poultry Health Laboratory, in collaboration with other U.S. and Canadian universities and with support from the U.S. Department of Agriculture and the Arkansas Economic Development Commission, Kemin said.
"Partnering with PGT on this vaccine will allow Kemin to deliver the technology needed to address salmonella contamination in poultry, a common pathogen that threatens food safety and the health of consumers," Kemin president and chief executive officer Dr. Chris Nelson said. "I am thrilled that we will be able to bring this vaccine to market around the world. This will make the vaccine more accessible, which, in turn, may help reduce the incidence rate of salmonella in consumer poultry products."
As part of its partnership with PGT, Kemin will focus on developing the salmonella vaccine and registering it in the U.S. and other countries, beginning with the European Union. Kemin will also begin expanding the salmonella vaccine's availability in Southeast Asia and Africa.
"Kemin has the technology, technical expertise and scientific experience to scale PGT's salmonella vaccine and deliver it to a global audience," PGT CEO Tim Collard said. "We are excited to partner with Kemin because we believe that the superiority of our vaccine, coupled with Kemin's innovation, commitment to animal health and global presence, can make salmonella prevention more attainable for many."
Kemin Biologics, a business initiative of Kemin Industries focused on developing vaccines as the first line of defense against disease, entered this partnership with PGT in February 2020 and has begun the product registration process in multiple countries, the announcement said.